500+ ADC Experts, 50+ Leading Speakers: Join the World's Largest ADC Meeting

Following a blockbuster 2011 that saw Adcetris gain approval and heavyweights Genmab, Abbott and Novartis weigh in, all eyes are looking at ADCs in 2012.

Headline domination is set to continue with Pfizer and Genentech both expecting FDA decisions on CMC-544 and T-DM1.  And with so much money at stake and a burgeoning market to capitalize on, antibody and oncology drug developers large and small are fighting to grab share in this exploding sector.

That’s why every serious player in the ADC market chooses to attend 5^th World ADC.  Bringing you the cutting edge of ADC science this is the forum for ADC developers to meet, learn and do business. 

Hear what attendees had to say about last year's meeting:

"Great meeting. I have been working in this field for over 10 years, this meeting brings the best scientists with state of the art experience. Finally a meeting where we can focus on just ADC. Great job"
Bristol Myers Squibb

“The ADC Forum exceeded my expectations. Access to cutting edge developments and interaction between the attendees were all top notch! I will attend in 2012”.
Igenica, Inc.

But why is 5^th World ADC the only ADC meeting you need to attend in 2012?

With so much exciting work to highlight we’ll be running multiple streams at the conference to ensure you can sit in on the topics that are most important to you. On the agenda for this year is:

• A commercial program exploring partnering & licensing, drug marketing & reimbursement ^{New for 2012}
• Antibody engineering strategies to optimize ADC performance ^{New for 2012}
• Company updates on the latest clinical trial performances ^Updated
• More networking time then ever before: Speed networking, 1to1s, a networking dinner, a poster session & a drinks reception ^Updated
• The latest strategies in ADC bioprocessing, handling, analytical characterization & outsourcing
• Insights from clinic and preclinic on drug PK and metabolism of linker, payload & mAb
• Technology presentations on the cutting edge linker and payload platforms ^{Perfect for newcomers}
• Innovations in target selection, drug delivery & MOA ^{Perfect for newcomers}

Leave with all of the information and contacts you need to drive progress in your business.

World ADC Summit Advisory Board

• John Lambert, Executive Vice President & Chief Scientific Officer, ImmunoGen
• Paul Polakis, Director, Cancer Targets, Genentech
• Hans Peter Gerber, Senior Director, Bioconjugates and Vascular Biology, Pfizer
• Sanjeev Gangwar, Senior Director, Medicinal Chemistry, Bristol-Myers Squibb
• Dennis Benjamin, Senior Director, Experimental Therapies, Seattle Genetics
• Peter Senter, Vice President, Chemistry, Seattle Genetics
• Alain Beck, Head of Physico-Chemistry Department, Pierre Fabre
• Mike Sun, Associate Director, Seattle Genetics

How can you get involved?

1. Firstly, let us know if you’ve got material that you’re interested in presenting as there are opportunities to speak or sponsor.
2. Why not join our community on LinkedIn and join over 1000 of you peers - start discussions, find answers and make new contacts. Simply search groups Antibody Drug Conjugates 
3. Secure your place early and take advantage of the early registration discounts.  Our 2010 and 2011 meetings sold out so don’t be disappointed